The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: -10.50 (-0.59%)
Spread: 0.50 (0.028%)
Open: 1,796.00
High: 1,808.50
Low: 1,772.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Covid-19 Hit Sends National Express Lower

Thu, 13th Aug 2020 11:02

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

Just Eat Takeaway, up 2.6%. The online food delivery platform was counting gains after it posted positive interim results on Wednesday. The stock closed up 3.7% on Wednesday.

----------

FTSE 100 - LOSERS

----------

Phoenix Group, down 3.7%, Legal & General, down 1.8%, Aviva, down 2.3%. GlaxoSmithKline, down 2.3%. Royal Dutch Shell A, down 2.2%, Shell B, down 2.1%. The stocks listed in this section all went ex-dividend on Thursday, meaning new buyers no longer qualify for the latest payout.

----------

FTSE 250 - WINNERS

----------

Watches of Switzerland, up 16%. The luxury timepiece retailer said it delivered a strong performance in its maiden year as a public company. For the financial year ended April 26, revenue was up 6% to GBP819.3 million from GBP797.7 million in financial 2019, and adjusted pretax profit was GBP49.4 million, up 86% from GBP26.5 million. For financial 2021, Watches of Switzerland expects revenue in a range between GBP840 million to GBP860 million, on the basis of a continued strong luxury watch market in the UK and US. The company re-opened the majority of its stores during the first quarter, with July registering 7.4% growth in sales versus a year ago, the first full month when the majority of the network was re-opened. June sales were up 0.3%, while May registered a 83% drop.

----------

FTSE 250 - LOSERS

----------

National Express, down 12%. The transport company swung to a bruising loss during a first-half that was focused on limiting the damage from Covid-19, which has battered the public transport sector. The bus, coach and train operator swung to a GBP122.2 million pretax loss in the six months to June 30 from a GBP88.4 million profit a year earlier. Revenue dropped 23% to GBP1.03 billion from GBP1.34 billion. There was no interim dividend, as previously guided, following a 5.16p payout a year ago. There is also no annual profit guidance, due to Covid-19 uncertainty.

----------

Renishaw, down 11%. The British engineering company warned of the continuation of "very challenging" macroeconomic conditions due to the Covid-19 pandemic. For the financial year that ended June 30 pretax profit fell to GBP3.2 million down 97% from GBP109.9 million recorded a year ago. The sharp drop was attributed to restructuring costs, losses in value of financial instruments and financial expenses. Annual revenue fell 11% to GBP510.2 million from GBP574.0 million. Metrology division revenue was lower by 11% at GBP475.2 million, largely as a result of trade tensions between the US and China, weaker demand in the machine tool sector, and the impact of the pandemic. Healthcare revenue decreased by 15% to GBP35.0 million, with Covid-19 causing delays in orders, shipments, installations and postponements of elective surgery. It stated that a final dividend will not be declared in 2020.

----------

TUI, down 4.2%. The Anglo-German holiday firm offered a bleak picture to investors after third-quarter results highlighted how severely hit the travel sector was due to Covid-19 lockdown. Tui reported a pretax loss of EUR1.46 billion for the period ended June 30, swinging from a EUR60 million profit a year before, as revenue plunged 98% to EUR75 million. Third-quarter underlying loss before interest and tax amounted to EUR1.1 billion due to suspension of operations for the majority part of the quarter, resulting in impairment charges and costs arising from ineffective hedging contracts. For the nine months to June-end, the company's revenue fell 41% To EUR6.71 billion, resulting in a sharply widened pretax loss of EUR2.34 billion from a EUR323.3 million loss a year ago. The nine-month underlying Ebit loss amounted to EUR2.0 billion, an increase of EUR1.8 billion versus a year prior, reflected underlying costs of EUR1.3 billion from business suspension since March, impairments triggered totalling EUR410 million, and net costs from ineffective hedges amounting to EUR189 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

ASOS, up 3.5%. The online fashion retailer was upgraded to Hold from Sell by Liberum. ASOS on Wednesday said its annual sales and profit are likely to be "significantly ahead of market expectations" as customer returns did not increase as fast as expected.

----------

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
30 Apr 2024 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more
24 Apr 2024 14:19

UK earnings, trading statements calendar - next 7 days

Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
Loungers PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham House Energy Storage Fund PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Close Brothers Group PLCTrading Statement
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Strip Tinning Holdings PLCFull Year Results
Whitbread PLCFull Year Results
Wednesday 1 May 
Computacenter PLCTrading Statement
GSK PLCQ1 Results
Haleon PLCTrading Statement
HSS Hire Group PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Maintel Holdings PLCFull Year Results
Next PLCTrading Statement
Smith & Nephew PLCTrading Statement
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
24 Apr 2024 09:21

GSK's endometrial cancer drug receives FDA approval

(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.

Read more
24 Apr 2024 09:14

GSK's Jemperli with chemotherapy accepted for priority review by FDA

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jemperli, when used in combination with chemotherapy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.